Phase II Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatin/Paclitaxel with or without Daily Subcutaneous Amifostine in Patients with Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Robert Haddad, Lori Wirth, Rosemary Costello, Linda Weeks, Marshall Posner

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

The treatment of head and neck cancer continues to evolve. The recent use of aggressive chemoradiotherapy protocols has resulted in significant morbidity involving mucositis, dysphagia, and a higher rate of feeding tube dependency. We have initiated a randomized phase II study with concomitant chemoradiotherapy with or without subcutaneous amifostine (Ethyol, WR-2721; MedImmune, Inc, Gaithersburg, MD). This article presents a detailed background, rationale, and endpoints for this study and discusses future directions in the treatment of head and neck cancer.

Original languageEnglish
Pages (from-to)84-88
Number of pages5
JournalSeminars in Oncology
Volume30
Issue number6 SUPPL. 18
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Dive into the research topics of 'Phase II Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatin/Paclitaxel with or without Daily Subcutaneous Amifostine in Patients with Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck'. Together they form a unique fingerprint.

Cite this